About Flexion TherapeuticsFlexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive intra-articular (IA) injections for knee OA annually. Forward-Looking Statements Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to expectations regarding the completion, timing and proceeds of the public offering, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering; and other risks and uncertainties described in our filings with the SEC, including under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.
Investor ContactDavid CareyLazar Partners LTDT: 212-867-1768 email@example.comMedia ContactDanielle LewisLazar Partners LTDT: firstname.lastname@example.orgCorporate ContactFred DriscollChief Financial OfficerFlexion Therapeutics, Inc.T: email@example.com